Index

ABAS see Adaptive Behaviour Assessment System
Aberrant Behaviour Checklist (ABC) 149, 155
Abnormal Involuntary Movement Scale (AIMS) 195
absence seizures 37, 43, 53
acampirosate 212
acetylcholinesterase (AChE) inhibitors 69, 71, 227
acute mania 184–187
Adaptive Behaviour Assessment System (ABAS) 2, 138
Addison’s disease 187
ADHD see attention deficit hyperactivity disorder
AED see antiepileptic drugs
aggression 147–152
alcohol use disorders 204–205
attention deficit hyperactivity disorder 143
tobacco use disorders 128, 129
bipolar affective disorder 180, 183, 185, 188
definition 147
discussion case study 233
evidence base for medication
treatment 149–151
personality disorders 218–221, 223
prevalence 147–149
self-injurious behaviour 159
agitation 158, 166, 180
Aicardi syndrome 42, 242
AIMS see Abnormal Involuntary Movement Scale
alcohol use disorders 203–214
assessment 204, 206–207
clinical presentation 204–206
definition 203
diagnosis of dependence 203
discussion case study 239
epilepsy 49
management 207–209
prevalence 204, 207
risk factors 204, 206
role of medication 207, 210–212
sleep disorders 104, 209
withdrawal 208, 210–211, 213
Alzheimer’s disease (AD) 39–40, 64, 68, 70
see also dementia
amenorrhoea 107
amisulpride 201
amitriptyline 217
Angelman syndrome 42, 242
anopen 131
anti-androgens 119–122
anticholinergics 197–198
antidepressants
aggression 149, 151
alcohol use disorders 207
anxiety disorders 163–166
autism spectrum disorders 129–132
bipolar affective disorder 186
congenital malformations 172–173
definition 171
developmental delay 172–177
discontinuation reaction 173
duration and ending of treatment 173
discussion case study 239
personality disorders 217, 218, 222
prevalence 204, 207
risk factors 204, 206
role of medication 207, 210–212
schizophrenia 197
self-injurious behaviour 156–157
sexual offending 119
sleep disorders 99, 103
women’s health issues 112
antiepileptic drugs (AED)
alcohol use disorders 207, 211–212
autism spectrum disorders 131
epilepsy 39, 49, 53–58
prescribing practice 13
schizophrenia 197
antihistamines 99
antipsychotics 156–158
aggression 149–150
anxiety disorders 164–165
atypical antipsychotics 23, 201
augmentation strategies 200–201
autism spectrum disorders 130
bipolar affective disorder 180–181, 183–190
breast cancer 24–25
cardiovascular disease 24
dementia 71
drug interactions 196–197
hyperactivity disorder 143
glucose monitoring 24
high-dose antipsychotic therapy 26–29,
197–201

Edited by Sabyasachi Bhaumik, David Branford, Mary Barrett and Satheesh Kumar Gangadharan.
© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.
antipsychotics (cont’d)
  hyperprolactinaemia 24–25
  personality disorders 218, 221–222
  physical and health monitoring 23–29
  polypharmacy 27
  prevalence 23, 26–27
  schizophrenia 195–201
  sexual offending 119
  side effects 195–196, 198–201
  sleep disorders 99, 103
  switching antipsychotics 200
antisocial personality disorder 217
anxiety disorders 161–167
  alcohol use disorders 209
  autism spectrum disorders 231
  clinical presentation 161–162
  definition 161
  depression 170
  diagnostic criteria 161–162
  differential diagnosis 162
  discussion case study 234–235
  evidence base for medication treatment 163–165
  generalised anxiety disorder 165
  management 163–166
  obsessive-compulsive disorder 164
  panic disorder 165
  personality disorders 217, 218–220, 222
  prevalence 163
  psychosocial interventions 163
  self-injurious behaviour 158, 166
  women’s health issues 112
anxiolytics 112, 158
aphasia 66
apraxia 66
aripiprazole 130, 150, 156, 201
ASD see autism spectrum disorders
asphyxiation 80
atomoxetine 140–143, 232
atonic seizures 53
attention deficit hyperactivity disorder
  (ADHD) 135–145
  alcohol use disorders 206, 209–210
  clinical presentation 137
  definition 135
  diagnostic criteria 135–137
  differential diagnosis 137–138
  discussion case study 231–232
  dual diagnosis 138
  evidence base for medication treatment 140–143
  management 139–140
  NICE guidance 138, 139–143
  physical and health monitoring 22–23, 141, 143–144
  prevalence 138–139
  sleep disorders 100
atypical antipsychotics 23, 201
autism spectrum disorders (ASD) 125–133
aggression 128, 129
anxiety disorders 166
attention deficit hyperactivity disorder 138
clinical presentation 125–127
definition 125
depression 170, 171
discussion case study 230–231
eating and drinking difficulties 86
epilepsy 39, 52, 61
evidence base for medication treatment 129–132
management 128
prevalence 127
role of medication 128–129
schizophrenia 194
self-injurious behaviour 128, 129, 132, 155
sleep disorders 99, 104
women’s health issues 114
behavioural monitoring programmes 155–156
benign myoclonic epilepsy in infants 42
benzodiazepines
  alcohol use disorders 207, 209, 211
  anxiety disorders 163
  bipolar affective disorder 181–183, 185–187
  personality disorders 217
  sleep disorders 101
bereavement 172, 207, 235–236
bipolar affective disorder 179–191
  acute mania 184–187
  clinical presentation 180
  definition 179
  depression 187–188
  diagnostic criteria 180
  discussion case study 236–237
  electroconvulsive therapy 190–191
  evidence base for medication treatment 180–188
  hypomania 179–185
  mania 179–187
  mixed episodes 180, 188–191
  NICE guidance 181
  physical and health monitoring 181–182, 191
  prevalence 179
  prophylaxis 189
  rapid-cycling bipolar disorder 180, 188, 189–190
  rapid tranquillisation 181–183, 187
BNF see British National Formulary
borderline personality disorder 217
botulinum toxin 85
breast cancer 24–25
breastfeeding 120, 176, 200
British National Formulary (BNF) 26, 28, 196–197
buspirone 209
CAMDEX-DS 75
cannabis 104, 202, 209
capacity 8–9, 151
carbamazepine
Index 247

alcohol use disorders 211
bipolar affective disorder 181, 185, 186
dementia 71
epilepsy 53–55
physical and health monitoring 29
schizophrenia 200
women’s health issues 114
cardiovascular disease (CVD) 24
catamenial epilepsy 109, 229
catatonia 129
CBT see cognitive behaviour therapy
chest infections 79, 82
childhood
aggression 150
attention deficit hyperactivity disorder 138, 141–144
epilepsy 33–34, 40, 42, 44–45
prescribing practice 15
self-injurious behaviour 154
chloral hydrate 102
chlorzoxazone 213
chlormethiazole 211
choking 79, 86
chronotherapy 104
clobazam 55
clovalazepate 102
clomipramine 131, 156–159
clonazepam 55
clonidine 131, 143
clozapine 156, 198, 200–201
cognitive behaviour therapy (CBT) 139, 163, 236
combined oral contraceptive 112
communication 7, 14
community alcohol teams 208
complex epilepsy 114
compliance 196
computerised epilepsy (CT) 40
consent 7–8
Cornelia de Lange syndrome 154, 156, 242
corpus callosotomy 60
cough 79
covet medication 52
Cyproproterone acetate (CPA) see cyproterone acetate
CT see computerised tomography
CVD see cardiovascular disease
cyproterone acetate (CPA) 120, 122

Dementia Questionnaire for People with Learning Disabilities (DLD) 68–69, 74
depression 169–178
alcohol use disorders 209
autism spectrum disorders 170, 171
bipolar affective disorder 187–188
clinical presentation 170–171
concerns with antidepressants 172–173
definition 169
dementia 171
discontinuation reactions 173
discussion case study 235–236
Down syndrome 171
duration and ending of treatment 173
electroconvulsive therapy 175–177
epilepsy 171
evidence base for medication treatment 172
life events 172
NICE guidance 172, 177
prevalence 170
schizophrenia 171, 238
special patient groups 175–176
suicidality 172, 174
treatment with co-morbid conditions 175
dexamfetamine 140–142
Diagnostic and Statistical Manual (DSM)
attention deficit hyperactivity disorder 135–136, 138
bipolar affective disorder 180
dementia 63, 66
intellectual disability 1–2
personality disorders 216
sexual offending 117
women’s health issues 108
Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/Mental Retardation (DC-LD) 135–137, 138
diazepam 59
diet and nutrition see eating and drinking difficulties
dieticians 87–88
discontinuation reactions 173
Index

discussion case studies
  aggression 233
  alcohol use disorders 239
  anxiety disorders 234–235
  attention deficit hyperactivity disorder 231–232
  autism spectrum disorders 230–231
  bipolar affective disorder 236–237
  dementia 226–227
  depression 235–236
  eating and drinking difficulties 227
  epilepsy 225–226
  personality disorders 240
  schizophrenia 237–239
  self-injurious behaviours 233–234
  sexual offending 229–230
  sleep disorders 228
  women’s health issues 228–229

dispersible/disintegrating tablets 90–91

disulfiram 211

DLD see Dementia Questionnaire for People with Learning Disabilities

DLSQ see Daily Living Skills Questionnaire
donepezil 69
dopamine agonists 156

Down syndrome
  aetiology of intellectual disability 3
  definition 242
  dementia 64, 68, 70, 72, 74–75
  depression 171
  eating and drinking difficulties 91
  epilepsy 34, 36, 39–40, 56
  sleep disorders 97

Down Syndrome Dementia Scale (DSDS) 74

Down Syndrome Mental State Examination (DSMSE) 75

drug-induced psychosis 238
dry mouth 80, 82

DSDS see Down Syndrome Dementia Scale

DSM see Diagnostic and Statistical Manual

DSMSE see Down Syndrome Mental State Examination
dysphagia 77, 80–83, 87

early myoclonic encephalopathy 42
eating and drinking difficulties 77–93
  administration of medication via PEG tubes 89–91
  associated conditions 79–80
  choking 79, 86
  clinical presentation 77–79
  definition 77
  discussion case study 227
dysphagia 77, 80–83, 87
  feeding tubes 83, 87–91
  management strategies 87
  managing nutritional needs 82–83
  patient information 82
  prevalence 80–82
  reducing risks 83
  salivation management 80, 85–86
  swallowing medication 87, 88
  texture modification 83–84
  thickening drinks 84–85

ECG see electrocardiography

ECT see electroconvulsive therapy

EEG see electroencephalography
effervescent tablets 91

disorders 228

elderly people 200

see also dementia
electrocardiography (ECG)
  attention deficit hyperactivity disorder 139
  epilepsy 47
  physical and health monitoring 24, 28
  schizophrenia 196, 198
electroconvulsive therapy (ECT) 175–177, 190–191

electroencephalography (EEG)
  bipolar affective disorder 184
  epilepsy 31–32, 37–41, 46–48
  personality disorders 220
  sleep disorders 104
  epilepsy 31–62
  aetiology 34–36
  antiepileptic drugs 13, 39, 49, 53–58
  autism spectrum disorders 39, 52, 61
  bipolar affective disorder 187
  care plan 50
  catamenial epilepsy 109, 229
  classification of seizures 31–32
  clinical presentation 37
  correlation with intellectual disability 33
  covert medication 52
  definition 31
  depression 171
  differential diagnosis 37–38
  discussion case study 225–226
  Down syndrome 34, 36, 39–40, 56
  epidemiology 33–34
  frequency of seizures 36–37
  interactions between AEDs 57–58
  investigations 46–48
  management 50–51
  mental ill health and behaviour disorders 41, 46
  mortality 37, 48–49
  neurosurgery 59–60
  NICE guidance 48, 50, 54, 59
  non-epileptic attack 38–39
  pathogenesis of developmental epilepsy 36
  patient information 60–61
  polypharmacy 57
  prescribing practice 13
  prevalence 31–34
  principles of pharmacotherapy 51–52
  prolonged or repeated seizures 59
  psychosocial interventions 60
  refractory epilepsy 49, 59
  risk assessment 51
  schizophrenia 194, 200–201
seizure diary 50–51
self-injurious behaviour 155
sexual offending 123
side effects of AEDs 54–56
sleep disorders 104
starting treatment 52
sudden unexpected death in epilepsy 37, 48–49
suicidality 46
syndromes associated with ID and epilepsy 41–45, 54
therapeutic medication monitoring 57
women’s health issues 109, 114, 229
EPSE see extrapyramidal side effects
eslicarbazepine acetate 57
ethosuximide 55
exploitation 204–205
extrapyramidal side effects (EPSE) 195–196, 198, 201
febrile seizures 43
feeding tubes 83, 87–91
fluoxetine 217
focal resection 60
focal seizures 32
food loss 79
fragile X syndrome 3, 41, 154, 242
gabapentin 55, 211
GAD see generalised anxiety disorder
galantamine 69
generalised anxiety disorder (GAD) 165
gen eralised seizures 32, 43, 61
General Medical Council (GMC) 7
general practice 21–22
glucose monitoring 24
glycosylated haemoglobin (HBA1c) 24
GMC see General Medical Council
gonadotrophin-releasing hormone (GnRH) 113, 120
grandiosity 180
haloperidol 130, 149–150, 183, 201
HBA1c see glycosylated haemoglobin
HDAT see high-dose antipsychotic therapy
health inequality 21–22
health monitoring see physical and health monitoring
hemispherectomy 59–60
high-dose antipsychotic therapy (HDAT) 26–29, 197–201
holoprosencephaly 99
hormone therapy 112–113
hyoscine 85
hyperandrogenism 229
hyperprolactinaemia 24–25
hypersalivation 85
hypersomnia 103–104
hypnotics 101–103
hypomania 173, 179–184, 238
hyponatraemia 173
ICD see International Classification of Disease
ICSD see International Classification of Sleep Disorders
ID see intellectual disability
IGT see impaired glucose tolerance
IMCA see independent mental capacity advocate
impaired glucose tolerance (IGT) 23
independent mental capacity advocate (IMCA) 9
infection 79, 82
insomnia 96, 100–103, 209
intellectual disability (ID) 1–9
aetiology 3
capacity 8–9
communication 7
consent 7–8
diagnostic criteria and classification 1–2
evidence base for medication treatment 5
guidelines for medication treatment 6–7
health needs 4
key issues for healthcare workers 7–9
presentation of psychiatric and behavioural problems 4–5
prevalence 2
intelligence quotient (IQ) 1–2, 126, 204, 207
International Classification of Disease (ICD)
alcohol use disorders 203
attention deficit hyperactivity disorder 135–136, 138
dementia 66
intellectual disability 2
personality disorders 216
women’s health issues 108
International Classification of Sleep Disorders
(ICSD) 96
IQ see intelligence quotient
ketoadicosis 23
Kojewnikow’s syndrome 44
lacosamide 57
lamotrigine 29, 55, 131
language skills 194
Lennox–Gastaut syndrome 41, 43, 242
Lesch–Nyhan syndrome 154, 156, 243
levetiracetam 55
life events 172
lisdexamfetamine dimesylate 141–142
lithium
agression 151
bipolar affective disorder 180–181, 183–190, 237
personality disorders 220–222
physical and health monitoring 29
schizophrenia 197, 200
sexual offending 119
lorazepam 188
lung inflammation 81
magnetic resonance imaging (MRI) 37, 39–40, 46–47
Malnutrition Universal Screening Tool (MUST) 82
mania 179–187
MAOI see monoamine oxidase inhibitors
MDT see multidisciplinary team
medication-induced dysphagia 80, 82
medroxyprogesterone acetate (MPA) 119
melatonin 99–100
memantine 69, 71
MENCAP 4–5
menopause 109, 111, 113
menstrual cycle 107–109, 110–114
Mental Capacity Act 8, 52
Mental Health Act (1983) 9, 230
mental state examination (MSE) 166, 176
metabolic syndrome 23
metformin 113
methylphenidate 22–23, 131, 140–144, 232
midazolam 59
migrating partial epilepsy in infants 44
mixed episodes 180, 188–191
moclobemide 175
modafinil 104
monoamine oxidase inhibitors (MAOI) 173–176, 217
mood stabilisers
dementia 71
physical and health monitoring 29
self-injurious behaviour 155, 158
sexual offending 119
see also lithium; sodium valproate
MOSES see Multidimensional Observation Scale for Elderly Subjects
motivational interviewing 208
MPA see medroxyprogesterone acetate
MRI see magnetic resonance imaging
MSE see mental state examination
multi-agency working 230
Multidimensional Observation Scale for Elderly Subjects (MOSES) 74
multidisciplinary team (MDT)
eating and drinking difficulties 85, 87–88
epilepsy 52, 54, 60
MUST see Malnutrition Universal Screening Tool
myoclonic-astatic epilepsy 44
myoclonic seizures 37, 42–45, 53
NACHBID trial 149–150
naltrexone 159, 212, 221
narcolepsy 103–104
National Institute for Health and Clinical Excellence (NICE)
attention deficit hyperactivity disorder 138, 139–143
bipolar affective disorder 181
depression 172, 177
epilepsy 48, 50, 54, 59
intellectual disability 5, 7
sleep disorders 101
NEA see non-epileptic attack
neurosurgery 59–60
NICE see National Institute for Health and Clinical Excellence
NMDA antagonists 69
nocturnal epilepsy 104
non-epileptic attack (NEA) 38–39
nutrition see eating and drinking difficulties
obsessive–compulsive disorder (OCD) 119, 164
obstructive sleep apnoea (OSA) 97, 103
OCD see obsessive–compulsive disorder
oestradiol 113
Ohtahara syndrome 44
olanzapine
aggression 150–151
autism spectrum disorders 130
bipolar affective disorder 181, 183
dementia 71
personality disorders 217
self-injurious behaviour 156–158
opiate antagonists 156–158, 221
opioids 209
paedophilia 117–119, 122
pain 78
panic disorder 165
paranoia 86
paranoid schizophrenia 204, 238
paraphilias 117–123
parasomnias 104
paroxetine 173
partial seizures 32, 44, 53
PAS-ADD see Psychiatric Assessment Schedule for Adults with Developmental Disability
patient information 60–61, 82
PCOS see polycystic ovary syndrome
PEG see percutaneous endoscopic gastrostomy
pemoline 156
perampanel 57
percutaneous endoscopic gastrostomy (PEG) 83, 87–89
perimenopausal issues 109, 111, 113
personality disorders 215–224
antisocial personality disorder 217
anxious, fearful cluster 217
borderline personality disorder 217
clinical diagnosis-based medication treatment 216–217
definition 215
diagnostic criteria 216
discussion case study 240
flamboyant cluster 217
issues in diagnosis and treatment 218–222
key points specific to ID 215–216
odd, eccentric cluster 217
symptom-based medication treatment 217, 218
phenylketonuria (PKU) 34, 243
phobias 161
physical and health monitoring 21–30
adverse drug reactions 27
antipsychotics 23–29
attention deficit hyperactivity disorder 141, 143–144
bipolar affective disorder 181–182, 191
general physical monitoring 21–22
guidance for general practice 21–22
high-dose antipsychotic therapy 26–29
methylphenidate 22–23
mood stabilisers 29
polypharmacy 27
schizophrenia 195
physiotherapy 85
PKU see phenylketonuria
PMS see premenstrual syndrome
polycystic ovary syndrome (PCOS) 109, 113, 229
polypharmacy 12–13, 27, 57
polysomnography 103
posture 85
poverty 206
Prader–Willi syndrome 148, 154, 243
pregabalin 55
pregnancy 56, 183–184, 200
premenstrual syndrome (PMS) 107–109, 110–114, 229
prescribing practice 11–19
adverse reactions 13–14
categories of psychotropic medication use 12
children 15
communication 14
definition 11
evidence base for medication treatment 14
high-dose antipsychotic therapy 27–28
key guidelines 16–17
overprescription 12
polypharmacy 12–13
prevalence 11
review effectiveness 14–15
Royal College of Psychiatrists guidance 18
progestosterone 112, 114
prolonged seizures 59
propranolol 155, 158, 165, 235
Psychiatric Assessment Schedule for Adults with Developmental Disability (PAS-ADD) 188
psychogenic non-epileptic attack 38–39
psychosis
alcohol use disorders 239
drug-induced psychosis 238
personality disorders 220–222
women’s health issues 109
see also schizophrenia
psychosocial interventions
alcohol use disorders 208
anxiety disorders 163
attention deficit hyperactivity disorder 139
dementia 72
depression 236
epilepsy 60
schizophrenia 238
sexual offending 122
psychotic depression 174
pyridoxine deficiency 34
quetiapine 130, 150, 157–158
rapid-cycling bipolar disorder 180, 188, 189–190
rapid-cycling mood disorders 155
rapid eye movement (REM) 104
rapid tranquillisation 181–183, 187
Rasmussen’s syndrome 44
RCPsych see Royal College of Psychiatrists
refractory epilepsy 49, 59
REM see rapid eye movement
repeated seizures 59
repetitive behaviours 129, 132, 151, 158
respiration monitoring 49
retigabine 57
Rett syndrome 41, 44, 154, 243
risk assessment 51, 129, 148–149
risperidone 71, 130, 149–151, 156, 158, 201
rivastigmine 69
Rubinstein–Taybi syndrome 80, 97, 243
salivation management 80, 85–86
SASQ see Single Alcohol Screening Questionnaire
schizophrenia 193–202
aetiology 194
alcohol use disorders 204
atypical presentations 194
augmentation strategies 200–201
cognition 196
definition 193
depression 171
discussion case study 237–239
drug interactions 196–197
duration of treatment 201
evidence base of medication treatment 197–202
key points specific to ID 194–195
management 195–197
physical and health monitoring 23
schizophrenia (cont’d)
prevalence 193–194
side effects of medication 195–196, 198–201
special patient groups 201
switching antipsychotics 200
second-generation antipsychotics (SGA) 71
sedative hypnotics 101
seizure diary 50–51
selective noradrenaline reuptake inhibitors (SNRI) 112–113, 140–143, 173
selective serotonin reuptake inhibitors (SSRI) 71
aggression 151
alcohol use disorders 207, 212
anxiety disorders 163–166
autism spectrum disorders 129, 130, 132
dementia 71
depression 172–177
personality disorders 217, 218, 222
self-injurious behaviour 156–157
sexual offending 119
women’s health issues 112–113
self-injurious behaviour (SIB) 153–160
anxiety disorders 158, 166
assessment and management 154–155
autism spectrum disorders 129, 132, 155
behavioural monitoring programmes 155–156
biological model 154, 156, 158–159
clinical presentation 153–154
clinical subtypes 154, 156, 158–159
definition 153
depression 172
discussion case study 233–234
evidence base for medication treatment 156–159
personality disorders 220, 222
prevalence 154
Self-Injury Trauma Scale 155
sensitisation 85
sertraline 71, 119
severe myoclonic epilepsy in infancy 45
sexual abuse 206
sexual offending 117–124
aetiology 118
anti-androgens 119–122
definition 117
discussion case study 229–230
evidence base for medical treatment 119–123
paraphilias 117–123
prevalence 118	
treatment of sexual offenders 118–119
SGA see second-generation antipsychotics
SIB see self-injurious behaviour
Single Alcohol Screening Questionnaire (SASQ) 204
sleep disorders 95–106
alcohol use disorders 104, 209
antidepressants 99, 103
antipsychotics 99, 103
autism spectrum disorders 231
clinical presentation 96–97
definition 95–96
discussion case study 228
hypersomnia 103–104
hypnotics 101–103
insomnia 96, 100–103, 209
management 97–99
medication strategies 99
melatonin 99–100
narcolepsy 103–104
NICE guidance 101
obstructive sleep apnoea 97, 103
parasomnias 104
prevalence 97
sedative hypnotics 101
sleep–wake cycle disturbances 99, 104
SLT see speech and language therapy
Smith–Magenis syndrome 154, 243
SMR see standardised mortality rates
SNRI see selective noradrenaline reuptake inhibitors
social exclusion 206
social phobia 209
sodium valproate
aggression 151
alcohol use disorders 211
autism spectrum disorders 131
bipolar affective disorder 180–190
dementia 71
depression 177
epilepsy 53–54, 56
personality disorders 220–222
physical and health monitoring 29
schizophrenia 200
women’s health issues 114
speech and language therapy (SLT)
anxiety disorders 235
eating and drinking difficulties 82, 85, 227
epilepsy 225–226
spironolactone 112, 113
SSRI see selective serotonin reuptake inhibitors
standardised mortality rates (SMR) 48
stereotypies 129
stimulants
alcohol use disorders 209–210
attention deficit hyperactivity disorder 100, 140–144, 209–210
autism spectrum disorders 131
sleep disorders 100
see also methylphenidate
Sturge–Weber syndrome 41, 45, 244
substance use 104, 202, 205, 209
see also alcohol use disorders
sudden unexpected death in epilepsy (SUDEP) 37, 48–49
suicidality
alcohol use disorders 204–205
depression 172, 174
epilepsy 46
sleep disorders 104
sulpiride 200
surgical diversion of salivary glands 85
swallowing difficulties see dysphagia
syndromal autism 39

TCA see tricyclic antidepressants
temperament–character–intelligence (TCI) model 218
teratogenicity 56, 183–184
testosterone 118
Tests for Severe Impairment (TSI) 75
texture modification 83–84
therapeutic amenorrhoea 107
therapeutic medication monitoring 57
thiazolidinediones 113
thickening drinks 84–85
tiagabine 56
tonic–clonic seizures 37, 49, 53, 59, 61
tonic seizures 53
topiramate 56
triclofos sodium 102
tricyclic antidepressants (TCA) 156–157, 172–176
triptorelin 120, 122
TSI see Tests for Severe Impairment
tuberous sclerosis 34, 41, 244

urea and electrolytes (U&E) 29

VABS see Vineland Adaptive Behaviour Scales
vagal nerve stimulation (VNS) 59–60
valproate see sodium valproate

Vineland Adaptive Behaviour Scales (VABS) 2, 74, 138
vitamins 239
VNS see vagal nerve stimulation

WAIS see Wechsler Adult Intelligence Scale
Wechsler Adult Intelligence Scale (WAIS) 118
weight gain 23
weight loss 78, 82
Wernicke Korsakoff’s psychosis 239
West syndrome 45, 244
Williams syndrome 97, 244
Wing’s triad of impairments 125
women’s health issues 107–115
adolescence and puberty 108, 111
catamenial epilepsy 109
childbearing years 109, 111
definitions and aetiology 107–109
discussion case study 228–229
issues specific to intellectual disability 110
key issues through the life cycle 109
management 110–113
menstrual cycle and premenstrual syndrome 107–109, 110–114, 229
perimenopausal issues 109, 111, 113
polycystic ovary syndrome 109, 113, 229
schizophrenia 200

zaleplon 101
ziprasidone 157
zolpidem 101
zonidamide 56
zopiclone 101
zuclopenthixol 151, 221